Product B

Drug Profile

Product B

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sylentis
  • Class Anti-inflammatories; Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Crohn's disease
  • Research Arthritis
  • Discontinued Ulcerative colitis

Most Recent Events

  • 12 Jul 2016 Product B is still in early research for Arthritis in Spain
  • 12 Jul 2016 Product B is still in preclinical trials for Crohn's disease in Spain
  • 12 Jul 2016 Discontinued - Preclinical for Ulcerative colitis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top